Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Efficacy and safety of a novel ĸ-agonist for managing intractable pruritus in dialysis patients.

Kumagai H, Ebata T, Takamori K, Miyasato K, Muramatsu T, Nakamoto H, Kurihara M, Yanagita T, Suzuki H.

Am J Nephrol. 2012;36(2):175-83. doi: 10.1159/000341268. Epub 2012 Aug 3.

2.

Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study.

Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H.

Nephrol Dial Transplant. 2010 Apr;25(4):1251-7. doi: 10.1093/ndt/gfp588. Epub 2009 Nov 19.

3.

Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients.

Nakao K, Mochizuki H.

Drugs Today (Barc). 2009 May;45(5):323-9. doi: 10.1358/dot.2009.45.5.1362067. Review.

PMID:
19584962
4.

[Pharmacological and clinical profiles of nalfurafine hydrochloride (Remitch) capsules 2.5 microg) , a new therapeutic agent for the treatment of uremic pruritus in hemodialysis patients].

Nakao K, Ando A, Hirakata M, Ando N, Takeshita K, Miyamoto Y, Mochizuki H.

Nihon Yakurigaku Zasshi. 2010 May;135(5):205-14. Review. Japanese. No abstract available.

PMID:
20467170
5.

Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies.

Wikström B, Gellert R, Ladefoged SD, Danda Y, Akai M, Ide K, Ogasawara M, Kawashima Y, Ueno K, Mori A, Ueno Y.

J Am Soc Nephrol. 2005 Dec;16(12):3742-7. Epub 2005 Oct 26.

6.

Nalfurafine hydrochloride for the treatment of pruritus.

Inui S.

Expert Opin Pharmacother. 2012 Jul;13(10):1507-13. doi: 10.1517/14656566.2012.693164. Epub 2012 Jun 5. Review.

PMID:
22663138
7.

One year long-term study on abuse liability of nalfurafine in hemodialysis patients.

Ueno Y, Mori A, Yanagita T.

Int J Clin Pharmacol Ther. 2013 Nov;51(11):823-31. doi: 10.5414/CP201852.

PMID:
24040851
8.

Spontaneous scratching behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel kappa-opioid receptor agonist nalfurafine hydrochloride.

Umeuchi H, Kawashima Y, Aoki CA, Kurokawa T, Nakao K, Itoh M, Kikuchi K, Kato T, Okano K, Gershwin ME, Miyakawa H.

Eur J Pharmacol. 2005 Aug 22;518(2-3):133-9.

PMID:
16055114
9.

Nalfurafine hydrochloride to treat pruritus: a review.

Inui S.

Clin Cosmet Investig Dermatol. 2015 May 11;8:249-55. doi: 10.2147/CCID.S55942. eCollection 2015. Review.

10.

Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review.

Phan NQ, Lotts T, Antal A, Bernhard JD, Ständer S.

Acta Derm Venereol. 2012 Sep;92(5):555-60. doi: 10.2340/00015555-1353. Review.

11.

A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch.

Murphy M, Reaich D, Pai P, Finn P, Carmichael AJ.

Br J Dermatol. 2003 Feb;148(2):314-7.

PMID:
12588385
12.
13.

A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients.

Young TA, Patel TS, Camacho F, Clark A, Freedman BI, Kaur M, Fountain J, Williams LL, Yosipovitch G, Fleischer AB Jr.

J Dermatolog Treat. 2009;20(2):76-81. doi: 10.1080/09546630802441218.

PMID:
18821119
14.

[Pharmacological effects of nalfurafine hydrochloride, a kappa-opioid receptor agonist].

Nakao K, Hasebe K, Yoshikawa S, Ikeda K, Hirakata M, Miyamoto Y, Mochizuki H.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Nov;30(5-6):185-91. Review. Japanese.

PMID:
21226314
15.

Efficacy and safety of a new kappa-opioid receptor agonist for the treatment of uremic pruritus.

Delmez JA.

Nat Clin Pract Nephrol. 2006 Jul;2(7):358-9. No abstract available.

PMID:
16932462
16.

Molecule of the Month. Nalfurafine hydrochloride.

[No authors listed]

Drug News Perspect. 2009 Dec;22(10):619. No abstract available.

PMID:
20140281
17.

Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study.

Pauli-Magnus C, Mikus G, Alscher DM, Kirschner T, Nagel W, Gugeler N, Risler T, Berger ED, Kuhlmann U, Mettang T.

J Am Soc Nephrol. 2000 Mar;11(3):514-9.

18.

Effect of nalfurafine hydrochloride on pruritus and anxiety level in hemodialysis patients.

Inui S, Shirakawa Y, Itami S.

J Dermatol. 2012 Oct;39(10):886-7. doi: 10.1111/j.1346-8138.2011.01442.x. Epub 2011 Dec 5. No abstract available.

PMID:
22142516
19.

Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus.

Hawi A, Alcorn H Jr, Berg J, Hines C, Hait H, Sciascia T.

BMC Nephrol. 2015 Apr 8;16:47. doi: 10.1186/s12882-015-0043-3.

20.

Sericin cream reduces pruritus in hemodialysis patients: a randomized, double-blind, placebo-controlled experimental study.

Aramwit P, Keongamaroon O, Siritientong T, Bang N, Supasyndh O.

BMC Nephrol. 2012 Sep 24;13:119. doi: 10.1186/1471-2369-13-119.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk